APP and Alzheimer disease: Because dysregulation of mitochondrial Ca2+ has been recently implicated at the more advanced disease stages in the APP/PS1 model and in patients with AD (Calvo-Rodriguez et al., 2020), DHODH inhibitors may be powerful blockers of activity-dependent mitochondrial Ca2+ overload (Styr et al., 2019).